发明公开
EP3197917A1 BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING CD19 AND CD3, AND USES THEREOF
审中-公开
具有结合CD19和CD3能力的双特异性双价糖尿病及其用途
- 专利标题： BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING CD19 AND CD3, AND USES THEREOF
- 专利标题（中）： 具有结合CD19和CD3能力的双特异性双价糖尿病及其用途
-
申请号： EP15844698.9申请日： 2015-09-22
-
公开(公告)号： EP3197917A1公开(公告)日： 2017-08-02
- 发明人: JOHNSON, Leslie, S. , BONVINI, Ezio , LAM, Chia-ying, Kao , MOORE, Paul, A. , LIU, Liqin , KOENIG, Scott
- 申请人： MacroGenics, Inc.
- 申请人地址： 9704 Medical Center Drive Rockville, MD 20850 US
- 专利权人： MacroGenics, Inc.
- 当前专利权人： MacroGenics, Inc.
- 当前专利权人地址： 9704 Medical Center Drive Rockville, MD 20850 US
- 代理机构： Atkinson, Jennifer
- 优先权： US201462055695P 20140926
- 国际公布： WO2016048938 20160331
- 主分类号： C07K16/28
- IPC分类号： C07K16/28
摘要：
CD 19×CD3 bi-specific monovalent diabodies, and particularly, CD 19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD 19 and CD3, and are used in the treatment of hematologic malignancies.
公开/授权文献
信息查询
